Human chronic chagasic cardiopathy: participation of parasite antigens, subsets of lymphocytes, cytokines and microvascular abnormalities

Higuchi, Maria de Lourdes

doi:10.1590/s0074-02761999000700044

Cited by 26 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An exacerbated type 1 specific response against T. cruzi has been associated with cardiomyopathy in human disease, as well as in experimental infections (1,4,15,16,26,27,31). Recent studies with human T-cell clones suggest that CCR5 or CXCR3 chemokine receptors may be markers for type 1 response, and CCR3, CCR4, and CCR8 are corresponding markers for type 2 immune response (6,28,29,38).…”

Section: Discussionmentioning

confidence: 99%

“…Regardless of the primary mechanism involved on the development of chronic cardiomyopathy i.e., whether due to parasite persistence or a contributing role of autoimmunity, several studies have suggested a predominance of gamma interferon (IFN-␥) production in tissue and peripheral cells of chagasic cardiac patients compared to infected asymptomatic indeterminate individuals (1,4,15,16,19,26,27).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Type 1 Chemokine Receptor Expression in Chagas' Disease Correlates with Morbidity in Cardiac Patients

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Type 1 Chemokine Receptor Expression in Chagas' Disease Correlates with Morbidity in Cardiac Patients

et al. 2005

View full text Add to dashboard Cite

“…These questions were in relation to: epidemiology (12), clinical characteristics (13), anatomopathological characteristics (11), chemotherapy and prevention (12) and not answered (4). The responses showed that there were striking differences in the prevalence and morbidity of Chagas disease, with regard to both heart disease and megas, with greater severity of the disease in countries south of the Equator.…”

Section: Morbidity Differences In Chagas Disease According To Geograpmentioning

confidence: 99%

Chagas disease: What is known and what should be improved: a systemic review

Coura

Borges-Pereira

2012

Rev. Soc. Bras. Med. Trop.

118

View full text Add to dashboard Cite

This study consists of a broad review on what is known and what should be improved regarding knowledge of Chagas disease, not only through analysis on the main studies published on the topics discussed, but to a large extent based on experience of this subject, acquired over the past 50 years (1961-2011). Among the subjects covered, we highlight the pathogenesis and evolution of infection by Trypanosoma cruzi, drugs in use and new strategies for treating Chagas disease; the serological tests for the diagnosis and the controls of cure the infection; the regional variations in prevalence, morbidity and response to treatment of the disease; the importance of metacyclogenesis of T. cruzi in different species of triatomines and its capacity to transmit Chagas infection; the risks of adaptation of wild triatomines to human dwellings; the morbidity and need for a surveillance and control program for Chagas disease in the Amazon region and the need to prioritize initiatives for controlling Chagas disease in Latin America and Mexico and in non-endemic countries, which is today a major international dilemma. Finally, we raise the need for to create a new initiative for controlling Chagas disease in the Gran Chaco, which involves parts of Argentina, Bolivia and Paraguay.

show abstract

“…T. cruzi is estimated to affect ϳ20 million people, mainly in the areas of South and Central America, Mexico, and the southern United States (47,48). Upon infection, human patients exhibit acute flu-like symptoms and then enter an indeterminate phase wherein they exhibit no clinical disease symptoms (19,35). Approximately 40% of the infected patients, however, progress to the chronic phase, which is characterized by myocardial inflammation, fibrosis and necrosis, and cardiac dysfunction, eventually leading to heart failure (19,33).…”

mentioning

confidence: 99%

“…Upon infection, human patients exhibit acute flu-like symptoms and then enter an indeterminate phase wherein they exhibit no clinical disease symptoms (19,35). Approximately 40% of the infected patients, however, progress to the chronic phase, which is characterized by myocardial inflammation, fibrosis and necrosis, and cardiac dysfunction, eventually leading to heart failure (19,33). Chemotherapies for the treatment of both acute and chronic patients are of limited use due to high toxicity and poor efficacy of the available drugs (40).…”

mentioning

confidence: 99%

Utility of the Trypanosoma cruzi Sequence Database for Identification of Potential Vaccine Candidates by In Silico and In Vitro Screening

Bhatia¹,

Sinha²,

Luxon³

et al. 2004

Infect Immun

108

View full text Add to dashboard Cite

Glycosylphosphatidylinositol (GPI)-anchored proteins are abundantly expressed in the infective and intracellular stages of Trypanosoma cruzi and are recognized as antigenic targets by both the humoral and cellular arms of the immune system. Previously, we demonstrated the efficacy of genes encoding GPI-anchored proteins in eliciting partially protective immunity to T. cruzi infection and disease, suggesting their utility as vaccine candidates. For the identification of additional vaccine targets, in this study we screened the T. cruzi expressed sequence tag (EST) and genomic sequence survey (GSS) databases. By applying a variety of web-based genomemining tools to the analysis of ϳ2,500 sequences, we identified 348 (37.6%) EST and 260 (17.4%) GSS sequences encoding novel parasite-specific proteins. Of these, 19 sequences exhibited the characteristics of secreted and/or membrane-associated GPI proteins. Eight of the selected sequences were amplified to obtain genes TcG1, TcG2, TcG3, TcG4, TcG5, TcG6, TcG7, and TcG8 (TcG1-TcG8) which are expressed in different developmental stages of the parasite and conserved in the genome of a variety of T. cruzi strains. Flow cytometry confirmed the expression of the antigens encoded by the cloned genes as surface proteins in trypomastigote and/or amastigote stages of T. cruzi. When delivered as a DNA vaccine, genes TcG1-TcG6 elicited a parasitespecific antibody response in mice. Except for TcG5, antisera to genes TcG1-TcG6 exhibited trypanolytic activity against the trypomastigote forms of T. cruzi, a property known to correlate with the immune control of T. cruzi. Taken together, our results validate the applicability of bioinformatics in genome mining, resulting in the identification of T. cruzi membrane-associated proteins that are potential vaccine candidates.

show abstract

Human chronic chagasic cardiopathy: participation of parasite antigens, subsets of lymphocytes, cytokines and microvascular abnormalities

Cited by 26 publications

References 21 publications

Type 1 Chemokine Receptor Expression in Chagas' Disease Correlates with Morbidity in Cardiac Patients

Type 1 Chemokine Receptor Expression in Chagas' Disease Correlates with Morbidity in Cardiac Patients

Chagas disease: What is known and what should be improved: a systemic review

Utility of the Trypanosoma cruzi Sequence Database for Identification of Potential Vaccine Candidates by In Silico and In Vitro Screening

Contact Info

Product

Resources

About